Monsey

Researchers are evaluating real-world treatment patterns, effectiveness, and side effects of xanomeline and trospium chloride (KarXT) in adults diagnosed with schizophrenia in the United States. This study aims to describe how patients respond to KarXT treatment and the related adverse events as observed in routine clinical care. Participants receive xanomeline and trospium chloride (KarXT) following the product label instructions. They may either be starting KarXT treatment within 16 weeks with plans to stop previous antipsychotics or already on a stable antipsychotic regimen and switching to KarXT under their clinician's guidance. Other psychiatric medications like antidepressants or mood stabilizers can be continued at stable doses during the study. During the study, participants' treatment adjustments and switches are tracked from baseline up to 20 weeks. Researchers monitor treatment effectiveness and safety through regular clinical follow-up, recording any changes, side effects, or adverse events. The study relies on the treating clinician’s judgment to assess treatment progress and participant safety throughout the observation period.